Category: Industry News
-
Key Insights from FDA’s Psychedelic Drug Hearing
On September 14, 2026, the FDA hosted a public hearing on psychedelic drug therapy considerations, attracting 80 speakers who debated training, safety, access, and data standards. Consensus emerged on the need for interdisciplinary care and robust safety measures post-treatment. The hearing emphasized that effective psychedelic care relies on integrated systems rather than isolated approaches.
-
From Cannabis to Psilocybin: What Schedule III Rescheduling for Cannabis Tells Us About the Road Ahead
The federal rescheduling of medical cannabis from Schedule I to Schedule III is the most consequential shift in U.S. controlled substance policy in over fifty years. For those building the infrastructure for legal psilocybin medicine, it is also the clearest map yet of where this field is headed. The banking barriers, insurance gaps, and tax…